Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The objective of this study was to test the efficacy of intravenously administered S-adenosyl-L-methionine (SAMe) in patients with fibromyalgia (FM). Thirty-four out-patients with fibromyalgia symptoms received SAMe 600 mg i.v. or placebo daily for 10 days in a cross-over trial. There was no significant difference in improvement in the primary outcome: tender point change between the two treatment groups. There was a tendency towards statistical significance in favour of SAMe on subjective perception of pain at rest (p = 0.08), pain on movement (p = 0.11), and overall well-being (p = 0.17) and slight improvement only on fatigue, quality of sleep, morning stiffness, and on the Fibromyalgia Impact Questionnaire for pain. No effect could be observed on isokinetic muscle strength, Zerrsen self-assessment questionnaire, and the face scale. No effect of SAMe in patients with FM was found in this short term study.

Original publication

DOI

10.3109/03009749709065682

Type

Journal article

Journal

Scand J Rheumatol

Publication Date

1997

Volume

26

Pages

206 - 211

Keywords

Adult, Aged, Cross-Over Studies, Double-Blind Method, Female, Fibromyalgia, Humans, Injections, Intravenous, Male, Middle Aged, Pain, Pain Measurement, S-Adenosylmethionine, Severity of Illness Index, Surveys and Questionnaires, Treatment Outcome